IMvigor130: Updated OS Data From the Final Analysis
A post hoc analysis of the IMvigor130 trial examined overall survival (OS) outcomes by response during first-line induction atezolizumab or placebo plus platinum-based chemotherapy induction for patients with metastatic urothelial carcinoma (mUC). Results of the analysis are being presented at the American Society of Clinical Oncology 2023 Annual Meeting. ...
Advertisement
Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Zachary BessetteASCO 2023 | June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Read More
Emily MenendezASCO 2023 | June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Emily MenendezASCO 2023 | June 1, 2023
Results of the STARTAR phase 2 trial on salvage RT plus apalutamide and docetaxel were presented at the 2023 ASCO meeting.
Emily MenendezASCO 2023 | June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.

Video Insights

Clinical discussions with experts in the field